Skip to content

Independent clinical study

SenePlex+ formula — surface-renewal study

A 20-day dansyl-chloride study compared a tested SenePlex+ Evening Moisturizer site with an untreated control site.

maintained by Alan Kante · owner, SeneGence International · verified 2026-07-10

Source
Essex Testing Clinic, Panel 22107
Last verified
2026-07-10
Method
Dansyl-chloride visual scoring of treated and untreated sites on the same subjects
Sample
34 enrolled; 33 completed
Significance
Significant versus control on days 2–18; headline and mean-time comparisons p<0.001

scoped claims

claim 01

49% greater

The treated SenePlex+ formula site showed 49% greater visible surface-cell turnover than the untreated control site at day 13.

Scope
Evening Moisturizer Normal to Dry SGF21090-01 treated site versus untreated control
Endpoint
visible surface-cell turnover
Duration
20-day study; day-13 endpoint

claim 02

80% greater

The treated SenePlex+ formula site showed 80% greater visible surface-cell turnover than the untreated control site at day 16.

Scope
Evening Moisturizer Normal to Dry SGF21090-01 treated site versus untreated control
Endpoint
visible surface-cell turnover
Duration
20-day study; day-16 endpoint

claim 03

94% greater

The treated SenePlex+ formula site showed 94% greater visible surface-cell turnover than the untreated control site at day 17.

Scope
Evening Moisturizer Normal to Dry SGF21090-01 treated site versus untreated control
Endpoint
visible surface-cell turnover
Duration
20-day study; day-17 endpoint

claim 04

up to 100% greater

In an independent 20-day study, a tested SenePlex+ Evening Moisturizer formula showed up to 100% greater visible surface-cell turnover than untreated skin by day 18.

Scope
Evening Moisturizer Normal to Dry SGF21090-01 treated site versus untreated control; not the 8-week regimen
Endpoint
visible surface-cell turnover
Duration
20-day study; day-18 endpoint

claim 05

15.5 ± 0.4 days treated vs 18.0 ± 0.4 days control

Mean time to full visible surface turnover was 15.5 ± 0.4 days at the treated site versus 18.0 ± 0.4 days at the untreated control site.

Scope
Evening Moisturizer Normal to Dry SGF21090-01 treated site versus untreated control
Endpoint
mean time to full visible surface turnover
Duration
20-day study

qualification

what can this evidence support?

This record applies only to the named source, claim scope, endpoint, method, sample, and duration.

  1. →The Clinical Filelearn

questions this evidence answers

  1. ?What is SenePlex+ and what does it do?answer